Vertex Non Current Liabilities Total vs Asset Turnover Analysis
VRTX Stock | USD 401.08 0.92 0.23% |
Vertex Pharmaceuticals financial indicator trend analysis is much more than just breaking down Vertex Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Vertex Pharmaceuticals is a good investment. Please check the relationship between Vertex Pharmaceuticals Non Current Liabilities Total and its Asset Turnover accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vertex Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.
Non Current Liabilities Total vs Asset Turnover
Non Current Liabilities Total vs Asset Turnover Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Vertex Pharmaceuticals Non Current Liabilities Total account and Asset Turnover. At this time, the significance of the direction appears to have almost no relationship.
The correlation between Vertex Pharmaceuticals' Non Current Liabilities Total and Asset Turnover is 0.16. Overlapping area represents the amount of variation of Non Current Liabilities Total that can explain the historical movement of Asset Turnover in the same time period over historical financial statements of Vertex Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Vertex Pharmaceuticals' Non Current Liabilities Total and Asset Turnover is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Current Liabilities Total of Vertex Pharmaceuticals are associated (or correlated) with its Asset Turnover. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Asset Turnover has no effect on the direction of Non Current Liabilities Total i.e., Vertex Pharmaceuticals' Non Current Liabilities Total and Asset Turnover go up and down completely randomly.
Correlation Coefficient | 0.16 |
Relationship Direction | Positive |
Relationship Strength | Insignificant |
Non Current Liabilities Total
Asset Turnover
The ratio of net sales to average total assets, indicating how efficiently a company uses its assets to generate sales.Most indicators from Vertex Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Vertex Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vertex Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.At this time, Vertex Pharmaceuticals' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 798.2 M in 2024, whereas Discontinued Operations is likely to drop (861.8 K) in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 6.7B | 7.9B | 8.6B | 9.0B | Total Revenue | 7.6B | 8.9B | 9.8B | 10.3B |
Vertex Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Vertex Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Vertex Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 8.3B | 11.8B | 13.4B | 18.2B | 22.7B | 23.9B | |
Short Long Term Debt Total | 577.4M | 581.5M | 556.7M | 561M | 808.4M | 848.8M | |
Other Current Liab | 1.0B | 1.2B | 1.5B | 1.9B | 2.9B | 3.1B | |
Total Current Liabilities | 1.2B | 1.6B | 1.9B | 2.4B | 3.5B | 3.7B | |
Total Stockholder Equity | 6.1B | 8.7B | 10.1B | 13.9B | 17.6B | 18.5B | |
Property Plant And Equipment Net | 745.1M | 958.5M | 1.1B | 1.1B | 1.5B | 1.5B | |
Net Debt | (2.5B) | (5.4B) | (6.2B) | (9.9B) | (9.6B) | (9.1B) | |
Retained Earnings | (1.9B) | 858.7M | 3.2B | 6.5B | 10.1B | 10.6B | |
Cash | 3.1B | 6.0B | 6.8B | 10.5B | 10.4B | 10.9B | |
Non Current Assets Total | 3.7B | 3.9B | 4.4B | 5.5B | 8.6B | 9.0B | |
Non Currrent Assets Other | 326.9M | 662.5M | 901.1M | 1.3B | 796.7M | 836.5M | |
Cash And Short Term Investments | 3.8B | 6.7B | 7.5B | 10.8B | 11.2B | 11.8B | |
Common Stock Shares Outstanding | 260.7M | 263.4M | 259.9M | 259.1M | 260.5M | 153.1M | |
Liabilities And Stockholders Equity | 8.3B | 11.8B | 13.4B | 18.2B | 22.7B | 23.9B | |
Non Current Liabilities Total | 1.0B | 1.5B | 1.5B | 1.8B | 1.6B | 1.7B | |
Other Current Assets | 213.5M | 308.4M | 187.2M | 74.4M | 620.5M | 651.5M | |
Other Stockholder Equity | 7.9B | 7.9B | 6.9B | 7.4B | 7.4B | 7.8B | |
Total Liab | 2.2B | 3.1B | 3.3B | 4.2B | 5.1B | 5.4B | |
Total Current Assets | 4.6B | 7.8B | 9.0B | 12.7B | 14.1B | 14.9B | |
Short Term Debt | 30.3M | 42.4M | 46.9M | 89.4M | 83.7M | 51.0M | |
Accounts Payable | 87.6M | 155.1M | 195M | 303.9M | 364.9M | 383.1M | |
Property Plant And Equipment Gross | 745.1M | 958.5M | 2.3B | 2.5B | 2.6B | 2.8B | |
Accumulated Other Comprehensive Income | (2.0M) | (68.5M) | 15.9M | 800K | (14.3M) | (13.6M) | |
Net Receivables | 633.5M | 885.4M | 1.1B | 1.4B | 1.6B | 1.6B | |
Common Stock Total Equity | 2.6M | 2.6M | 2.5M | 2.6M | 3.0M | 1.9M | |
Common Stock | 2.6M | 2.6M | 2.5M | 2.6M | 3.0M | 2.0M | |
Other Assets | 1.2B | 587.0M | 986.9M | 1.4B | 1.6B | 1.7B | |
Short Term Investments | 699.0M | 670.7M | 729.9M | 274.5M | 849.2M | 579.6M | |
Property Plant Equipment | 833.3M | 958.5M | 1.1B | 1.5B | 1.7B | 1.8B | |
Other Liab | 275.5M | 923.4M | 902.2M | 685.8M | 788.7M | 828.1M | |
Current Deferred Revenue | 62.3M | 191.5M | 171.7M | 159.6M | 170.3M | 118.8M | |
Inventory | 167.5M | 280.8M | 353.1M | 460.6M | 738.8M | 775.7M | |
Net Tangible Assets | 4.7B | 7.3B | 8.7B | 12.2B | 14.1B | 14.8B | |
Retained Earnings Total Equity | (1.9B) | 858.7M | 3.2B | 6.5B | 7.5B | 7.9B | |
Long Term Debt Total | 583.9M | 581.6M | 538.6M | 539.0M | 619.9M | 632.6M |
Vertex Pharmaceuticals Investors Sentiment
The influence of Vertex Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Vertex. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Vertex Pharmaceuticals' public news can be used to forecast risks associated with an investment in Vertex. The trend in average sentiment can be used to explain how an investor holding Vertex can time the market purely based on public headlines and social activities around Vertex Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Vertex Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Vertex Pharmaceuticals' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Vertex Pharmaceuticals' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Vertex Pharmaceuticals.
Vertex Pharmaceuticals Implied Volatility | 44.27 |
Vertex Pharmaceuticals' implied volatility exposes the market's sentiment of Vertex Pharmaceuticals stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Vertex Pharmaceuticals' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Vertex Pharmaceuticals stock will not fluctuate a lot when Vertex Pharmaceuticals' options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Vertex Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Vertex Pharmaceuticals' short interest history, or implied volatility extrapolated from Vertex Pharmaceuticals options trading.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Vertex Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Vertex Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vertex Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vertex Pharmaceuticals Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vertex Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Complementary Tools for Vertex Stock analysis
When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Transaction History View history of all your transactions and understand their impact on performance | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |
Is Vertex Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vertex Pharmaceuticals. If investors know Vertex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vertex Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.181 | Earnings Share 13.88 | Revenue Per Share 38.297 | Quarterly Revenue Growth 0.093 | Return On Assets 0.1317 |
The market value of Vertex Pharmaceuticals is measured differently than its book value, which is the value of Vertex that is recorded on the company's balance sheet. Investors also form their own opinion of Vertex Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Vertex Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vertex Pharmaceuticals' market value can be influenced by many factors that don't directly affect Vertex Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vertex Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vertex Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vertex Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.